SeekInCureTM
The first-in-class blood-based pan-cancer recurrence monitoring test
SeekInCureTM is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .
Add paragraph text here.
Specifications
◉ Indicated subjects: post-surgery cancer patients
◉ Sample requirement: 8ml peripheral blood
◉ Result readout: CRI (cancer recurrence index)
◉ Turnaround time (TAT): 10 working days
Sampling time
How it works
Pre-test inquiry
Informed consent
Blood-draw
Testing
Analyzing + Interpretation
Reporting
